Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Reimann P, et al. Among authors: schmidt s. Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38436671
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies.
Petzer V, Steiner N, Angelova-Unterberger O, Hetzenauer G, Philipp-Abbrederis K, Willenbacher E, Feistritzer C, Willenbacher W, Rudzki J, Stauder R, Kocher F, Seeber A, Pircher A, Tymoszuk P, Isara C, Egger A, Fux V, Anliker M, Gunsilius E, Nachbaur D, Schmidt S, Wolf D. Petzer V, et al. Among authors: schmidt s. Hemasphere. 2022 Feb 15;6(3):e686. doi: 10.1097/HS9.0000000000000686. eCollection 2022 Mar. Hemasphere. 2022. PMID: 35187405 Free PMC article. No abstract available.
[What's new in myeloproliferative neoplasia?].
Schmidt S, Wolf D. Schmidt S, et al. Dtsch Med Wochenschr. 2022 Mar;147(6):306-311. doi: 10.1055/a-1643-4357. Epub 2022 Mar 15. Dtsch Med Wochenschr. 2022. PMID: 35291035 German.
First annual report of the Austrian CML registry.
Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. Schmidt S, et al. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11. Wien Klin Wochenschr. 2010. PMID: 20936366
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Among authors: schmidt s. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. Ann Hematol. 2024. PMID: 38438627 Free PMC article.
HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation.
Clausen J, Böhm A, Straßl I, Stiefel O, Buxhofer-Ausch V, Machherndl-Spandl S, König J, Schmidt S, Steitzer H, Danzer M, Kasparu H, Weltermann A, Nachbaur D. Clausen J, et al. Among authors: schmidt s. Biomedicines. 2017 Mar 28;5(2):13. doi: 10.3390/biomedicines5020013. Biomedicines. 2017. PMID: 28536356 Free PMC article.
5,548 results